Podcasts about biogen inc

Britain's medicine regulator said Thursday that it approved a novel Alzheimer's drug developed jointly by Japanese drugmaker Eisai Co. and U.S. partner Biogen Inc.

アルツハイマー病治療薬「レカネマブ」【ロンドン時事】英医薬品・医療製品規制庁は２２日、日本の製薬大手エーザイなどが開発したアルツハイマー病治療薬「レカネマブ」を承認したと発表した。 Britain's medicine regulator said Thursday that it approved a novel Alzheimer's drug developed jointly by Japanese drugmaker Eisai Co. and U.S. partner Biogen Inc.

US equity markets retreated as a fresh rise in bond yields and ongoing concerns around instability in the Middle East overshadowed a strong first quarter result from investment banking major Goldman Sachs - Dow fell -248-points or -0.65%, relinquishing an earlier rally of over >1% to log a sixth straight session decline - the longest losing streak since June. Five (5) Dow components touched lows not seen in more than a year – Biogen Inc (down -0.70%), Boeing Co (-1.02%), Brown-Forman Corp (-0.08%), Verisign Inc (-1.20%) and Walgreens Boots Alliance Inc (-1.12%).

US equity markets retreated as a fresh rise in bond yields and ongoing concerns around instability in the Middle East overshadowed a strong first quarter result from investment banking major Goldman Sachs - Dow fell -248-points or -0.65%, relinquishing an earlier rally of over >1% to log a sixth straight session decline - the longest losing streak since June. Five (5) Dow components touched lows not seen in more than a year – Biogen Inc (down -0.70%), Boeing Co (-1.02%), Brown-Forman Corp (-0.08%), Verisign Inc (-1.20%) and Walgreens Boots Alliance Inc (-1.12%).

Dr. Ariel Dowling is a Senior Director and Head of the Sensing and Measurement group within the Data Sciences Institute at Takeda Pharmaceuticals ( https://www.takeda.com/our-impact/our-stories/integrating-data-sciences-into-clinical-development/ ). In this role, her group oversees the assessment, validation, and deployment of digital devices and endpoints across the organization. Dr. Dowling was previously a Senior Clinical Data Scientist at Biogen Inc. where she managed the wearable sensors deployed in clinical trials for Parkinson's Disease. She was also the algorithm team lead at MC10 Inc., a company developing thin, conformal electronics systems that flex, stretch, and bend seamlessly with the natural world, and worked at BioSensics LLC., a company developing of wearable sensors and digital platforms for clinical trials, patient monitoring and health assessment. Dr. Dowling holds an MS and Ph.D. in Mechanical Engineering from Stanford University, an AB and BE in Mechanical Engineering from Dartmouth College, and did post-doctoral work in robotics at Technion in Israel. She currently serves on the Strategic Advisory Board of the Digital Medicine (DiMe) Society. Support the show

Synopsis: Keith Gottesdiener, MD, and Jeremy Duffield, MD, PhD, FRCP, are the President & CEO and CSO, respectively, of Prime Medicine. Prime Medicine was founded to bring the promise of gene editing to patients. They use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Keith and Jeremy discuss the arc of their careers and how they go to where they are today. They talk about the differences working in big pharma vs. a smaller biotech like Prime. They discuss the importance of companies investing in safety and what they've learned in terms of indication selection frameworks within the context of gene editing. Finally, they talk about their goal of engaging in partnerships down the road, and the importance of having transparency within their organization. Biography: Keith Gottesdiener, MD is President and Chief Executive Officer of Prime Medicine and has served as a member of our Board of Directors since July 2020. From October 2011 until March 2020, Dr. Gottesdiener served as the Chief Executive Officer and a director of Rhythm Pharmaceuticals, Inc., a biopharmaceutical company that develops therapeutics in rare genetic obesity. During that time, Rhythm submitted a New Drug Application for setmelanotide in two indications, for which setmelanotide was subsequently approved. Dr. Gottesdiener received his B.A. from Harvard College and his M.D. from the University of Pennsylvania. He completed his residency and fellowship at the Brigham and Women's Hospital-Beth Israel Medical Center-Dana Farber Cancer Institute Children's Hospital programs. After his fellowship, Dr. Gottesdiener did postdoctoral research in the laboratory of Dr. Jack Strominger at the Dana Farber Cancer Institute. He then joined the faculty as an assistant professor at Columbia University, where he started an independent research laboratory with NIH RO-1 funding, ending his academic career as Associate Clinical Professor of Medicine at the time he left to join Merck in 1995. Jeremy Duffield, MD, PhD, FRCP, is the Chief Scientific Officer of Prime Medicine. He has many years of drug discovery experience at Vertex Pharmaceuticals and Biogen Inc. preceded by a distinguished career in academic medicine. Dr. Duffield has held several leadership roles, with focus in the fields of human genetics, innate immunity and regenerative medicine. He served as Global Head of Human Biology at Vertex Pharmaceuticals and as Vice President of Business Development where he and his team played important roles in discovering and advancing candidates to clinical studies in rare diseases including cystic fibrosis, a1-antitrypsin deficiency, sickle cell disease, FSGS and muscular dystrophies. Several candidates are now approved therapies. He was instrumental in building Vertex Cell and Genetic Therapies. At Biogen, Dr. Duffield served as Senior Research Fellow and Vice President with responsibilities in early research programs, as joint Head of Innate Immunity and Regenerative Medicine therapeutic area, and as Head of the Biogen Post-Doctoral program. There he contributed to advancing integrin inhibitors, TNF superfamily inhibitors and IRAK inhibitors to clinical evaluation for pulmonary fibrosis and autoimmune diseases. Dr. Duffield received his B.A. and M.D. (B.M., B.Ch.) from Oxford University and a Ph.D. in Immunology from the University of Edinburgh in the laboratory of Sir John Savill.

Biogen Inc., Q2 2023 Earnings Call, Jul 25, 2023

Eisai Co., Ltd. and Biogen Inc. announced on January 6th that under the Accelerated Approval Pathway the U.S. Food and Drug Administration (FDA) has approved lecanemab-irmb, which has the brand name in the United States of LEQEMBITM, for the treatment of Alzheimer's disease.  The approval is based on Phase 2 data that demonstrated that LEQEMBI reduced the accumulation of Aβ plaque in the brain, a defining feature of Alzheimer's disease.  Newt's guest is Dr. Marwan Sabbagh, MD.  He is a behavioral neurologist in the Alzheimer's and Memory Disorders Program and a professor in the Department of Neurology at Barrow Neurological Institute and was one of the leading doctors of the study.See omnystudio.com/listener for privacy information.

製薬大手エーザイなどが開発したアルツハイマー病治療薬「レカネマブ」製薬大手エーザイは７日、米バイオ医薬品大手バイオジェンと共同開発したアルツハイマー病治療薬「レカネマブ」が米食品医薬品局に迅速承認されたと発表した。 The U.S. Food and Drug Administration on Friday approved a new drug for Alzheimer's disease jointly developed by Japanese drugmaker Eisai Co. and U.S. biopharmaceutical company Biogen Inc.

製薬大手エーザイなどが開発したアルツハイマー病治療薬「レカネマブ」製薬大手エーザイは７日、米バイオ医薬品大手バイオジェンと共同開発したアルツハイマー病治療薬「レカネマブ」が米食品医薬品局に迅速承認されたと発表した。 The U.S. Food and Drug Administration on Friday approved a new drug for Alzheimer's disease jointly developed by Japanese drugmaker Eisai Co. and U.S. biopharmaceutical company Biogen Inc.

The U.S. Food and Drug Administration on Friday approved a new drug for Alzheimer's disease jointly developed by Japanese drugmaker Eisai Co. and U.S. biopharmaceutical company Biogen Inc.

Iran's national soccer team faces retribution in the Islamic Republic after coming up short in Tuesday's showdown against the United States. Internet users in China will soon be held liable for liking posts deemed illegal or harmful, sparking fears that the world's second largest economy plans to control social media like never before. In a phase III clinical trial, with results published Tuesday in the New England Journal of Medicine, the drug, Lecanemab -- developed by Eisai and Biogen Inc. -- slowed the rate of cognitive decline by 27% in patients in the early stages of the disease, making it the first drug of its kind to produce such positive trial results, the study showed.See omnystudio.com/listener for privacy information.

Biogen Inc., Q3 2022 Earnings Call, Oct 25, 2022

Top Geothermal and Medical Stocks podcast includes these articles: “6 Best Geothermal Stocks To Buy”; “12 Best Ethical Stocks To Buy Now”; “The biggest carbon losers”; “Amid Fixed Income Calamity, Green Bonds Look Interesting”; “5 green companies to invest in and why they will multiply your investment by 20x”; plus, UK articles and more Podcast: Top Geothermal and Medical Stocks Transcript & Links, Episode 92, October 21, 2022 Hello, Ron Robins here. Welcome to my podcast episode 92 published on October 21, 2022, titled “Top Geothermal and Medical Stocks” — and presented by Investing for the Soul. Investingforthesoul.com is your site for vital global ethical and sustainable investing mentoring, news, commentary, information, and resources. Remember that you can find a full transcript, and links to content – including stock symbols and bonus material – on this episode's podcast page located at investingforthesoul.com/podcasts. Now if any terms are unfamiliar to you, simply Google them. Also, just a reminder. I do not evaluate any of the stocks or funds mentioned in these podcasts, nor do I receive any compensation from anyone covered in these podcasts. Furthermore, I will reveal to you any personal investments I have in the investments mentioned herein. Additionally, quotes about individual companies are brief so that I can get as many companies covered as possible in the time allowedFwor. Please go to this podcast's webpage for links to the actual articles where you'll find much more great company information. ------------------------------------------------------------- 1) Top Geothermal and Medical Stocks One type of terrific renewable energy getting increasing attention is geothermal. This is an interesting article on some of the top producers. It's titled 6 Best Geothermal Stocks To Buy by Hamna Asim on yahoo.com. Here are some quotes. “Geothermal energy refers to heat from within the sub-surface of the earth… However, electricity generation is possible only near active geothermal regions… We have arranged the list according to the hedge fund sentiment around the securities… assessed from Insider Monkey's database of 895 elite hedge funds tracked as of the end of the second quarter of 2022.  6. Ormat Technologies, Inc. (NYSE:ORA) Hedge Fund Holders: 17 Ormat Technologies was founded in 1965 and is based in Reno, Nevada. The company engages in the geothermal and recovered energy power businesses in the United States, Indonesia, Kenya, Turkey, Chile, Guadeloupe, Guatemala, Ethiopia, New Zealand, and Honduras… JPMorgan analyst Mark Strouse on August 8 raised the price target on Ormat Technologies, Inc. to $97 from $90 and maintained a Neutral rating on the shares… 5. Eversource Energy (NYSE:ES)  Hedge Fund Holders: 32 … is based in Springfield, Massachusetts, operating as a public utility holding company engaged in the energy delivery business… Eversource Energy's Geothermal Pilot Program will generate an affordable and low-carbon source of heating and cooling for residents and businesses… Eversource Energy delivers a 3.38% dividend yield as of October 6.  Mizuho analyst Paul Fremont raised the price target on Eversource Energy to $94 from $91 and reiterated a Neutral rating on the shares. 4. Chevron Corporation (NYSE:CVX) Hedge Fund Holders: 59 Chevron announced in February 2021 that it is making an investment in Baseload Capital AB, a Swedish private investment company engaged in developing and operating low-temperature geothermal and heat power assets. On September 26, Chevron Corporation and Mitsui Oil Exploration Co., Ltd. announced a Joint Collaboration Agreement to survey the technical and commercial suitability of advanced geothermal power generation in Japan… Piper Sandler analyst Ryan Todd on September 12 raised the price target on Chevron Corporation to $190 from $189 and kept an Overweight rating on the shares. 3. Berkshire Hathaway Inc. (NYSE:BRK-B) Hedge Fund Holders: 109 Berkshire Hathaway is a diversified American conglomerate with interests in multiple businesses including insurance, utilities, freight rail transportation, energy, and more. Berkshire Hathaway Energy generates, transmits, stores, and distributes electricity from natural gas, coal, wind, solar, hydroelectric, nuclear, and geothermal sources. Edward Jones analyst James Shanahan upgraded Berkshire Hathaway Inc. to Buy from Hold on September 12. 2. Polaris Renewable Energy Inc. (PIF.TO) Hedge Fund Holders: N/A Polaris Renewable Energy was incorporated in 1984 and is based in Toronto, Canada. The company engages in the acquisition and development of renewable energy projects in Latin America. Polaris Renewable Energy Inc. operates a 72 MW net geothermal facility in Nicaragua, as well as hydroelectric facilities and solar projects… On September 28, National Bank analyst Rupert Merer initiated coverage of Polaris Renewable Energy with an Outperform rating and a C$21 price target. 1. Climeon AB (publ) (STO:CLIME-B.ST) Hedge Fund Holders: N/A Climeon was founded in 2011 and is headquartered in Kista, Sweden. The company provides heat power systems in Sweden and the rest of Europe, as well as Asia. Climeon AB serves the geothermal, industrial processes, oil and gas, and maritime industries. Its Heat Power System technology utilizes low temperature geothermal energy and wasted heat energy emitted from engines and industrial processes to produce electricity.” End quotes. ------------------------------------------------------------- 2) Top Geothermal and Medical Stocks Here's another article by Insider Monkey. This is titled 12 Best Ethical Stocks To Buy Now and is seen on yahoo.com. Here is a quote on their methodology and brief comments on each of their picks. Incidentally, only two are non-medical. “We… ranked them from #12 to #1 based on the number of hedge fund holders in our database that held each stock at the end of Q2 2022. 12. GlaxoSmithKline plc (NYSE:GSK) Hedge Fund Holders: 34 GlaxoSmithKline develops, manufactures and markets pharmaceutical products, vaccines, over the counter medicines and health related consumer products globally. 11. Deere & Company (NYSE:DE) Hedge Fund Holders: 54 Deere & Company manufactures agricultural machinery, heavy equipment, forestry machinery and more. 10. Biogen Inc. (NASDAQ:BIIB) Hedge Fund Holders: 54 Biogen discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. 9. Amgen, Inc. (NASDAQ:AMGN) Hedge Fund Holders: 55 Amgen discovers, develops manufactures and delivers human therapeutics worldwide. 8. Gilead Sciences, Inc. (NASDAQ:GILD) Hedge Fund Holders: 58 Gilead Sciences is a pharmaceutical company that discovers, develops, and commercializes medicines in areas of unmet medical need. 7. Bristol-Myers Squibb Company (NYSE:BMY) Hedge Fund Holders: 69 Bristol-Myers Squibb Company discovers, develops and markets biopharmaceutical products worldwide… the company offers products for hematology, oncology, cardiovascular, immunology and more. 6. Pfizer Inc. (NYSE:PFE) Hedge Fund Holders: 70 Pfizer discovers, develops, manufactures and sells biopharmaceutical products worldwide. The company… is also a leader in COVID-19 vaccines. 5. Eli Lilly and Company (NYSE:LLY) Hedge Fund Holders: 70 Eli Lilly and Company discovers, develops and markets human pharmaceuticals worldwide. 4. AbbVie Inc. (NYSE:ABBV) Hedge Fund Holders: 71 AbbVie discovers, develops, manufactures and sells pharmaceuticals worldwide… including potential therapies in blood cancer treatment. 3. Tesla, Inc. (NASDAQ:TSLA) Hedge Fund Holders: 72 Tesla is a leading electric vehicle manufacturer that also manufactures and sells battery energy storage and solar panels. 2. Merck & Co., Inc. (NYSE:MRK) Hedge Fund Holders: 79 Merck & Co. is a healthcare company with two segments, Pharmaceutical and Animal Health. Merck & Co., Inc.'s pharmaceutical segment offers products in areas such as oncology, hospital acute care, immunology, neuroscience and more. 1. Johnson & Johnson (NYSE:JNJ) Hedge Fund Holders: 83 Johnson & Johnson researches and develops and sells products in various healthcare fields worldwide. The company's pharmaceutical segment offers products and researches products for rheumatoid arthritis, inflammatory bowel disease, psoriasis and much more.” End quotes. ------------------------------------------------------------- The biggest carbon losers – by Corporate Knights Now many ethical and sustainable investors review the carbon intensities of companies before considering them for investment. In that light is this article. It's titled The biggest carbon losers. It's by Toby Heaps at Corporate Knights on corporateknights.com. Here are some quotes from the article. “This year, Corporate Knights set out to identify global companies that have decarbonized faster than their peers while simultaneously increasing revenue. Our researchers evaluated the greenhouse gas (GHG) emissions of more than 6,500 publicly traded companies. We eventually whittled the list down to 20 corporations from eight sectors that cut the most carbon over the last decade… Many are far from sustainability leaders. They're among the world's largest oil majors, coal burners and mining corporations. About two-thirds of the GHG reductions achieved by these companies were genuine from the planet's perspective… Italian electricity and gas distributor Enel topped the Carbon Reduction 20 ranking… According to calculations by Corporate Knights, these 20 companies funnelled just 35% of new investments in 2021 toward the sustainable, low-carbon economy, as defined by the Corporate Knights Sustainable Economy Taxonomy… 12 of the 20 funnelled more cash to shareholders and top executives than to growing their low-carbon sustainable business offerings… Note… we didn't include Scope 3.” End quotes. Incidentally, the list and details of the 20 companies are found at the bottom of the article. ------------------------------------------------------------- Amid Fixed Income Calamity, Green Bonds Look Interesting Now let's talk green bonds with this article titled Amid Fixed Income Calamity, Green Bonds Look Interesting. It's by Tom Lydon on etftrends.com. Now some quotes from Mr. Lydon. “Data suggest demand for green bonds is perking, indicating the VanEck Green Bond ETF (NYSEArca: GRNB) could be a fixed income exchange traded fund worthy of evaluation. (The fund) tracks the S&P Green Bond U.S. Dollar Select Index, is down year-to-date, but that negative performance could belie opportunity with green bonds. Additionally, data confirm some investors remain enthusiastic about this still young corner of the global bond market… ‘Companies and governments around the world raised more than $54 billion in green bonds last month, compared with more than $35 billion raised in August, data compiled by Bloomberg show. That's despite overall bond issuance in the U.S. and Europe dropping significantly…' reports David Caleb Mutua for Bloomberg.” End quotes. ------------------------------------------------------------- 5 green companies to invest in and why they will multiply your investment by 20x And, lastly, we have this article titled 5 green companies to invest in and why they will multiply your investment by 20x. It's by Market Trends on analyticsinsight.net. Here are some quotes on each of their picks which include some eco-tokens. “1) First Solar Inc. (ticker: FSLR) With a large manufacturing presence in the U.S., this solar panel builder will be among the biggest winners from the Inflation Reduction Act… The company stands alone in the industry with its differentiated semiconductor and streamlined manufacturing process, which yield unparalleled quality and reliability.  2) Tamadoge Tamadoge is the first meme coin with different features like metaverse, NFT store, and P2E crypto game setup with absolute utility… Since the Tamadoge ecosystem needs less energy to function, it ranks as the best eco-friendly crypto to buy during an energy crisis. 3) Powerledger (POWR) … was an Ethereum token established in 2016/17 that powers the Powerledger platform. It debuted on Coinbase in November 2021, with the token's price rising rapidly even while most cryptocurrencies fell in a market-wide crash.   4) Tesla Inc. (TSLA) Although competition has increased recently in the EV sector, there is still one undisputed king: Tesla… Plus, the company is a two-for-one green investment by making traditional solar panels as well as photovoltaic shingles. 5) IMPT.io IMPT.io connects users with hundreds of impactful environmental projects around the world with the purpose to reduce carbon emissions and help our planet. IMPT.io also engages thousands of the largest retail brands that allocate a specific percentage of sale margin for environmental projects.” End quotes. ------------------------------------------------------------- Other Honorable Mentions – not in any order 1) Title: GIS Named A Top Socially Responsible Dividend Stock on Nasdaq.com. By BNK Invest. 2) Title: 2 Renewable Energy Stocks To Watch This Week on Nasdaq.com. By Joe Samuel. UK article Title The magnificent seven: The top sustainable funds outperforming their sectors on Trustnet.com. By Matteo Anelli. ------------------------------------------------------------- Ending Comment Well, these are my top news stories with their stock and fund tips -- for this podcast: “Top Geothermal and Medical Stocks.” Now, please be sure to click the like and subscribe buttons on Apple Podcasts, Google Podcasts, or wherever you download or listen to this podcast. That helps bring these podcasts to others like you. And please click the share buttons to share this podcast with your friends and family. Let's promote ethical and sustainable investing as a force for hope in these deeply troubled times! Contact me if you have any questions. Thank you for listening. Talk to you next on November 4th. Bye for now. © 2022 Ron Robins, Investing for the Soul

This episode features Tim Fry, Healthcare Partner at McGuireWoods. Here, he discusses the president declaring that the pandemic is over & what that means for healthcare, investigations into provider relief programs, details surrounding the No Surprises Act, Biogen Inc. agreeing to pay $900 million to DOJ to settle False Claims Act allegations, and more.

新型のアルツハイマー病治療薬について記者会見するエーザイの内藤晴夫最高経営責任者、２８日午後、東京都文京区の同社本社製薬大手エーザイと米バイオ医薬品大手バイオジェンは２８日、共同開発中のアルツハイマー病治療薬「レカネマブ」について、後期段階の臨床試験で症状の悪化を抑制する効果が確認できたと発表した。 Japanese drugmaker Eisai Co. and U.S. biopharmaceutical company Biogen Inc. said Wednesday that an Alzheimer's drug they are jointly developing has been found effective in slowing the deterioration of symptoms in a late-stage clinical trial.

Japanese drugmaker Eisai Co. and U.S. biopharmaceutical company Biogen Inc. said Wednesday that an Alzheimer's drug they are jointly developing has been found effective in slowing the deterioration of symptoms in a late-stage clinical trial.

Biogen Inc., Q2 2022 Earnings Call, Jul 20, 2022

Biogen Inc., Q3 2021 Earnings Call, Oct 20, 2021

As researchers from more than 110 countries gathered for the Alzheimer's Association International Conference, new data estimate the number of people with dementia globally will triple to more than 152 million by 2050.In this episode, BioWorld Staff Writer Lee Landenberger spoke with Howard Fillit, founding executive director and chief science officer at the Alzheimer's Drug Discovery Foundation, which was created to accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease. The geriatrician, neuroscientist and Mount Sinai School of Medicine professor has led the foundation since it was formed in 1998. He's seen a lot of change in the R&D of dementia treatments and shared his insights about the importance of biomarkers, the controversy surrounding Biogen Inc.'s recently approved Aduhelm (aducanumab) and the impact of financial investments that drive the development of these therapies compared to other indications. See acast.com/privacy for privacy and opt-out information.

Biogen Inc., Q2 2021 Earnings Call, Jul 22, 2021

Approved Just one word caused a stock to rise more than 60% in one day. It's what happened earlier this week when the Food and Drug Administration signed off on Biogen Inc.'s (Nasdaq: BIIB) new Alzheimer's drug Aduhelm. Pro tip No. 1: I talked about the impact of this specific approval on Biogen and the broader biotech sector in a recent podcast. You can listen to that https://moneyandmarkets.com/biogen-stock-after-alzheimers-drug/ (here). However, an independent panel of medical experts https://www.cnbc.com/2020/11/06/biogen-suffers-setback-after-alzheimers-drug-fails-to-win-support-from-fda-panel-.html (did not endorse the finding), calling drug trial data “unconvincing.” Regardless of that criticism, this fast-track special consideration was a huge boost for Biogen's stock price. In today's episode of The Bull & The Bear, chief investment strategist Adam O'Dell, Green Zone Fortunes co-editor Charles Sizemore and I talk about Biogen's recent approval and how “novel” drugs can give biotech companies a leg up … and give substantial profit to investors. Be sure to also subscribe to our https://www.youtube.com/channel/UCt9RDMMAOPBAIWODmDGactQ?sub_confirmation=1 (YouTube channel) for more videos like my weekly Marijuana Market Update. Have something you want us to talk about? Email thebullandthebear@moneyandmarkets.com and give us your thoughts. Check out https://moneyandmarkets.com/ (moneyandmarkets.com), and sign up for our free newsletters that deliver you the most important and unbiased financial news, commentary, and actionable advice. Also, follow us on: https://www.facebook.com/moneyandmarkets (Facebook) https://twitter.com/TheMoneyMarkets (Twitter) https://www.linkedin.com/company/money-and-markets (LinkedIn)

The FDA's accelerated approval of Biogen Inc.'s Alzheimer's disease therapy, Aduhelm (aducanumab), is the first real beacon of hope in 18 years for the 50 million people living with the disease. But the approval was met with controversy over the drug's efficacy and pricing. Even as Biogen readies to launch in just two weeks with more than 900 sites lined up to start treating patients, a required confirmatory study could sink everything.BioWorld has been reporting on the development of Aduhelm since its discovery, by way of Neurimmune AG's reverse translational medicine technology. Later licensed to Biogen, it was co-developed with Eisai Co. Ltd.In this episode, News Editor Michael Fitzhugh talks with Ivana Rubino, Biogen's VP of global and U.S. medical affairs for Alzheimer's disease, about the approval, the controversies and what it all means for Biogen's future. See acast.com/privacy for privacy and opt-out information.

In November 2020, biotech analysts could not get enough of one particular stock after the company got a big break from the Food and Drug Administration (FDA). At the time, the FDA ruled it had enough evidence to support approval of Biogen Inc.'s (Nasdaq: BIIB) experimental Alzheimer's drug. On Monday, https://www.fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-new-treatment-alzheimers-disease (the government approved aducanumab), better known as Aduhelm. The announcement sent Biogen's stock through the roof. It jumped as much as 60% before cutting some of those gains. However, the approval came with two huge caveats: ·      https://www.cnbc.com/2020/11/06/biogen-suffers-setback-after-alzheimers-drug-fails-to-win-support-from-fda-panel-.html (An outside panel) of experts did not endorse the treatment. It said the data shown during drug trials were “unconvincing.” ·     Biogen executives said they https://www.barrons.com/articles/biogens-alzheimers-drug-price-backfire-51623155998 (were going to charge $56,000 per year) for the new treatment — five times more than expectations. In this episode of The Bull & The Bear, I examine the approval of this Alzheimer's treatment and what it means for Biogen and the broader biotech industry. I also tell you whether Biogen's stock is a buy or not after this big news. Be sure to also subscribe to our https://www.youtube.com/channel/UCt9RDMMAOPBAIWODmDGactQ?sub_confirmation=1 (YouTube channel) for more videos like my weekly Marijuana Market Update. Have something you want us to talk about? Email thebullandthebear@moneyandmarkets.com and give us your thoughts. Check out https://moneyandmarkets.com/ (moneyandmarkets.com), and sign up for our free newsletters that deliver you the most important and unbiased financial news, commentary, and actionable advice. Also, follow us on: https://www.facebook.com/moneyandmarkets (Facebook) https://twitter.com/TheMoneyMarkets (Twitter) https://www.linkedin.com/company/money-and-markets (LinkedIn)

US equity markets settled modestly weaker following a session absent any notable catalysts and as investors eye Thursday night's AEST (10 June) consumer price inflation (CPI) report for May - Dow lost -126-points or -0.36% to 34,630.24, having climbed above its 7 May record closing high (34,777.76) earlier in the session. The broader S&P500 dipped -0.08%, with Materials (down -1.23%) leading seven of the eleven primary sectors lower. Real Estate (up +0.91%) was the leading primary sector performer. Biogen Inc surged 38.3% following news that the Food and Drug Administration (FDA) approved its Alzheimer's disease drug aducanumab.

US equity markets settled modestly weaker following a session absent any notable catalysts and as investors eye Thursday night's AEST (10 June) consumer price inflation (CPI) report for May - Dow lost -126-points or -0.36% to 34,630.24, having climbed above its 7 May record closing high (34,777.76) earlier in the session. The broader S&P500 dipped -0.08%, with Materials (down -1.23%) leading seven of the eleven primary sectors lower. Real Estate (up +0.91%) was the leading primary sector performer. Biogen Inc surged 38.3% following news that the Food and Drug Administration (FDA) approved its Alzheimer's disease drug aducanumab.

Biogen Inc., Q1 2021 Earnings Call, Apr 22, 2021

Alex Denner is the Founder & Chief Investment Officer of Sarissa Capital Management, an activist firm investing in opportunities created by the unique dynamics of the healthcare sector. Alex also has a background in biomedical engineering. The estimated Net Worth of Alexander J Denner is at least $4.11 Billion dollars as of 26 February 2021. Alexander Denner owns over 1,350,000 units of Biogen Inc stock worth over $4,110,207,300 and over the last 12 years he sold BIIB stock worth over $1,800,788. ————————————————————————— To learn more about this episode, including podcast transcripts and show notes, visit *salt.org/talks* ( http://salt.org/talks ) Moderated by Anthony Scaramucci.

Biogen Inc. (NASDAQ: BIIB) Q3 2020 earnings call dated Oct. 21, 2020 Transcript: Click here Infographic: Click here Biogen tops market estimates in Q3, lowers guidance. Biogen (NASDAQ: BIIB) reported third-quarter 2020 financial results before the opening bell on Wednesday. The biotechnology giant reported a 6% decline in Q3 revenues to $3.38 billion, beating the Wall Street consensus. Earnings of $8.84 per share were also stronger than what analysts had anticipated. Corporate Participants: Joe Mara — Head of Investor Relations Michel Vounatsos — Chief Executive Officer Alfred W. Sandrock, Jr. — Executive Vice President Research & Development Michael McDonnell — Executive Vice President Chief Financial Officer Analysts: Terence Flynn — Goldman Sachs — Analyst Marc Goodman — SVB Leerink — Analyst Matthew Harrison — Morgan Stanley — Analyst Umer Raffat — Evercore ISI — Analyst Evan Seigerman — Credit Suisse — Analyst Phil Nadeau — Cowen & Company — Analyst Michael Yee — Jefferies — Analyst Cory Kasimov — JPMorgan — Analyst Ronny Gal — Bernstein — Analyst Geoff Meacham — Bank of America — Analyst Sumant Kulkarni — Canaccord — Analyst Jay Olson — Oppenheimer — Analyst Brian Abrahams — RBC Capital Markets — Analyst --- Send in a voice message: https://anchor.fm/earningspodcast/message Support this podcast: https://anchor.fm/earningspodcast/support

US markets traded mixed on Tuesday amid a flurry of earnings reports, news on Brexit and optimism that the U.S. and China were edging toward a resolution on bilateral trade.The Dow closed 37 points lower, or -0.15%, after rising more than 100 points earlier in the session. The broader S&P500, slid 0.36% to 2,995 though remains within striking distance of a record high hit in July. Through Tuesday morning, more than 19% of S&P 500 companies have reported quarterly numbers. Of those companies, nearly 80% have beaten analyst earnings expectations. The NASDAQ pulled back -0.72%. Drug maker, Biogen Inc. surged on news it will ask US drug regulators to approve the company's experimental Alzheimer's therapy reviving the nearly abandoned treatment after a new analysis of data from two failed clinical trials showed promising results. “We got clear support from the FDA,” Chief Executive Officer Michel Vounatsos said in a telephone interview. The move by Biogen -- if successful -- would be the drug industry's most dramatic reversal of fortune in history. Travelers, meanwhile, posted its worst day since 2008, plunging nearly 8%.